New antibody shows promise for Tough-to-Treat hodgkin lymphoma
NCT ID NCT05216835
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new drug called AZD7789 in 45 people with classical Hodgkin lymphoma that had returned or not responded to at least two prior treatments. The drug is a special antibody designed to help the immune system fight cancer cells. The main goals were to check safety and find the right dose, while also looking at whether the drug could shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RELAPSED OR REFRACTORY CLASSICAL HODGKIN LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Research Site
Duarte, California, 91010, United States
-
Research Site
Miami, Florida, 33136, United States
-
Research Site
Rochester, Minnesota, 55905, United States
-
Research Site
New York, New York, 10065, United States
-
Research Site
Houston, Texas, 77030, United States
-
Research Site
Toronto, Ontario, M5G 1X6, Canada
-
Research Site
Montreal, Quebec, H3T 1E2, Canada
-
Research Site
København Ø, 2100, Denmark
-
Research Site
Lille, 59037, France
-
Research Site
Bologna, 40138, Italy
-
Research Site
Naples, 80131, Italy
-
Research Site
Valencia, 46010, Spain
-
Research Site
Manchester, M20 4BX, United Kingdom
-
Research Site
Oxford, 0X3 7LJ, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.